CL2017000867A1 - Compositions of fatty acids and self-forming fatty acid ester of micelles and their use in the treatment of pathologies - Google Patents

Compositions of fatty acids and self-forming fatty acid ester of micelles and their use in the treatment of pathologies

Info

Publication number
CL2017000867A1
CL2017000867A1 CL2017000867A CL2017000867A CL2017000867A1 CL 2017000867 A1 CL2017000867 A1 CL 2017000867A1 CL 2017000867 A CL2017000867 A CL 2017000867A CL 2017000867 A CL2017000867 A CL 2017000867A CL 2017000867 A1 CL2017000867 A1 CL 2017000867A1
Authority
CL
Chile
Prior art keywords
compositions
disease
ester
fatty acid
omega
Prior art date
Application number
CL2017000867A
Other languages
Spanish (es)
Inventor
Frederick D Sancilio
Thorsteinn Thorsteinsson
Archibald Glynis Daniel
Toledano Miguel Lopez
Ahmed Abd Almalik Ahmed Mohammed Daak
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of CL2017000867A1 publication Critical patent/CL2017000867A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<p>EN EL PRESENTE DOCUMENTO SE DESCRIBEN COMPOSICIONES QUE INCLUYEN AL MENOS UN ÁCIDO GRASO OMEGA-3 (YA SEA EN FORMA DE TRIGLICÉRIDO, ÉSTER O ÉSTER DE ÁCIDO GRASO LIBRE) Y AL MENOS UN AGENTE TENSIOACTIVO; EN LAS QUE LAS COMPOSICIONES FORMAN MICELAS CUANDO ESTÁN EN CONTACTO CON UN MEDIO ACUOSO. TAMBIÉN SE PROPORCIONAN MÉTODOS DE ADMINISTRACIÓN A UN SUJETO DE UNA COMPOSICIÓN QUE INCLUYE AL MENOS UN ÁCIDO GRASO OMEGA-3 (YA SEA EN FORMA DE TRIGLICÉRIDO, ÉSTER O ÉSTER DE ÁCIDO GRASO LIBRE) Y AL MENOS UN AGENTE TENSIOACTIVO, EN LOS QUE LAS COMPOSICIONES FORMAN MICELAS CUANDO ESTÉN EN CONTACTO CON UN MEDIO ACUOSO Y LA BIODISPONIBILIDAD DEL ÁCIDO GRASO OMEGA-3 ES SUSTANCIALMENTE INDEPENDIENTE DE UN EFECTO DE LOS ALIMENTOS. LAS COMPOSICIONES SON ÚTILES PARA EL TRATAMIENTO DE CIERTAS PATOLOGÍAS QUE PUEDEN INCLUIR (1) SÍNDROMES DE MALABSORCIÓN, (2) COLANGITIS ESCLEROSANTE PRIMARIA (CEP), (3) HÍGADO GRASO NO ALCOHÓLICO (HGNA), 4) ENFERMEDAD DREPANOCÍTICA (ED), (5) DEGENERACIÓN MACULAR ASOCIADA A LA EDAD (DMAE). (6) ENFERMEDAD NEURODEGENERATIVA, INCLUYENDO LA ENFERMEDAD DE PARKINSON (EP), LA ENFERMEDAD DE ALZHEIMER (EA), LA ESCLEROSIS LATERAL AMIOTRÓFICA (ELA O ENFERMEDAD DE LOU GEHRIG). LA EPILEPSIA, EL SÍNDROME BIPOLAR, EL TRAUMATISMO CRANEOENCEFÁLICO, LA NEUROPATÍA PERIFÉRICA Y LA ESCLEROSIS MÚLTIPLE (EM). TAMBIÉN SE DESCRIBEN DIVERSAS FORMAS DE DOSIFICACIÓN PARA LA ADMINISTRACIÓN DE LAS COMPOSICIONES Y EL USO DE LAS COMPOSICIONES EN ALIMENTOS FUNCIONALES. EN EL PRESENTE DOCUMENTO TAMBIÉN SE PROPORCIONAN KITS CN INSTRUCCIONES PARA SU ADMINISTRACIÓN.</p><p> IN THIS DOCUMENT, COMPOSITIONS ARE DESCRIBED THAT INCLUDE AT LEAST ONE OMEGA-3 FATTY ACID (ALREADY IN THE FORM OF A TRIGLYCERIDE, ESTER OR ESTER OF FREE FATTY ACID) AND AT LEAST A TENSIOACTIVE AGENT; IN WHICH THE COMPOSITIONS FORM MICELAS WHEN THEY ARE IN CONTACT WITH A WATER MEDIA. METHODS OF ADMINISTRATION ARE ALSO PROVIDED TO A SUBJECT OF A COMPOSITION THAT INCLUDES AT LEAST ONE OMEGA-3 FAT ACID (ALREADY IN THE FORM OF A TRIGLYCERID, ESTER OR ESTER OF FREE FAT ACID) AND AT LEAST A TENSIOACTIVE AGENT WHICH THOSE They form micelles when they are in contact with an aqueous medium and the bioavailability of the OMEGA-3 fatty acid is substantially independent of an effect of food. THE COMPOSITIONS ARE USEFUL FOR THE TREATMENT OF CERTAIN PATHOLOGIES THAT MAY INCLUDE (1) MALABSORTION SYNDROMES, (2) PRIMARY SCLING COLANGITIS (CEP), (3) NON-ALCOHOLIC FAT LIVER (HGNA), 4) DREP DISEASE (DREP DISEASE) 5) AGE ASSOCIATED MACULAR DEGENERATION (DMAE). (6) NEURODEGENERATIVE DISEASE, INCLUDING PARKINSON'S DISEASE (EP), ALZHEIMER'S DISEASE (EA), AMIOTROPHIC LATERAL SCLEROSIS (ELA OR LOU GEHRIG'S DISEASE). EPILEPSY, BIPOLAR SYNDROME, CRANEOENCEPHALIC TRAUMATISM, PERIPHERAL NEUROPATHY AND MULTIPLE SCLEROSIS (MS). DIFFERENT DOSAGE FORMS ARE ALSO DESCRIBED FOR THE ADMINISTRATION OF COMPOSITIONS AND THE USE OF COMPOSITIONS IN FUNCTIONAL FOODS. KITS CN INSTRUCTIONS FOR ADMINISTRATION ARE ALSO PROVIDED IN THIS DOCUMENT. </p>

CL2017000867A 2014-10-10 2017-04-10 Compositions of fatty acids and self-forming fatty acid ester of micelles and their use in the treatment of pathologies CL2017000867A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462062634P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
CL2017000867A1 true CL2017000867A1 (en) 2017-11-03

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000867A CL2017000867A1 (en) 2014-10-10 2017-04-10 Compositions of fatty acids and self-forming fatty acid ester of micelles and their use in the treatment of pathologies

Country Status (8)

Country Link
EP (1) EP3212236A1 (en)
BR (1) BR112017007428A2 (en)
CA (1) CA2963952C (en)
CL (1) CL2017000867A1 (en)
MA (1) MA40846A (en)
MX (2) MX2017004324A (en)
WO (1) WO2016057915A1 (en)
ZA (1) ZA201702385B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 A kind of composition and its use, pharmaceutical preparation
AU2016406709C1 (en) * 2016-05-10 2023-04-27 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
US11241408B2 (en) 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
CN110312509A (en) * 2017-02-07 2019-10-08 费森尤斯卡比德国有限公司 Long-term efficacy of liver disease treatment with EPA and DHA
FR3092968B1 (en) * 2019-02-22 2021-05-21 Microphyt DIETARY SUPPLEMENT
IT201900007202A1 (en) * 2019-05-24 2020-11-24 Pavia Farm S R L COMPOSITION BASED ON LIPOSOLUBLE VITAMINS WITH HIGH ENTERIC ABSORPTION
MX2022001238A (en) 2019-08-13 2022-07-13 Team Foods Colombia Sa Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of non-alcoholic fatty liver disease (nafld).
CN115737555B (en) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 Cepharanthine self-microemulsion composition, preparation and preparation method thereof
CN117730823A (en) * 2022-09-20 2024-03-22 上海中医药大学 Modeling methods for primary sclerosing cholangitis combined with inflammatory bowel disease
WO2026030644A1 (en) * 2024-07-31 2026-02-05 Caper Labs, Inc. Arachidonic acid therapy for the treatment of neutropenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433630A4 (en) * 2009-05-22 2014-01-08 Mochida Pharm Co Ltd Self-emulsifying composition of 3 fatty acid
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
EP3072510B1 (en) * 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
CA2963952A1 (en) 2016-04-14
WO2016057915A1 (en) 2016-04-14
MX2020002238A (en) 2020-07-13
ZA201702385B (en) 2020-12-23
EP3212236A1 (en) 2017-09-06
MA40846A (en) 2017-09-05
MX2017004324A (en) 2017-07-04
CA2963952C (en) 2023-10-17
BR112017007428A2 (en) 2017-12-19

Similar Documents

Publication Publication Date Title
CL2017000867A1 (en) Compositions of fatty acids and self-forming fatty acid ester of micelles and their use in the treatment of pathologies
CO7121328A2 (en) Omega -3 fatty acid ester compositions
CL2019001447A1 (en) Preparation of solid cyclodextrin complexes for the supply of ophthalmic active pharmaceutical ingredients.
CY1123942T1 (en) OMEGA-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISEASES CAUSING DAMAGE TO THE NERVOUS SYSTEM
PH12018500090A1 (en) Nutritional compositions and methods for promoting cognitive development
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
PH12017500467A1 (en) Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of malabsorption or maldigestion in infants or children
AR105237A1 (en) METHOD AND NUTRITIONAL COMPOSITIONS CONTAINING PHOSFATIDYLETHANOLAMINE, SPPHINGOMYELINE AND DOCOSAHEXAENOIC ACID
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
MX2022011742A (en) NUTRITIONAL COMPOSITION FOR THE GASTROINTESTINAL ENVIRONMENT TO PROVIDE IMPROVED MICROBIOME AND METABOLIC PROFILE.
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
CL2018003537A1 (en) Lipids with an odd number of carbon atoms and their use as a pharmaceutical composition or as a nutritional supplement.
MX2021002902A (en) Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient.
CL2019000766A1 (en) Choline ester compositions of lipoic acid and methods for stabilizing in pharmaceutically relevant pharmacological products.
HK1244218A1 (en) Millicapsule formulations comprising polyunsaturated free fatty acids
AR100028A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING ESTEARIDÓNIC ACID
ES2527366B1 (en) Detergent composition comprising a biosurfactant of plant origin
CL2015001104A1 (en) Composition of fish feed
BR112018071142A2 (en) methods of manufacturing nutritional formulations
BR112018070194A2 (en) compound and composition for use
ECSP15011105A (en) siRNA AND ITS USE IN THE METHODS AND COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF EYE DISORDERS
AR097148A1 (en) FOOD COMPOSITION FOR RUMINANTS AND METHOD TO PREPARE IT
WO2015123480A3 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
TH128490A (en) A cleansing component containing polyglycerol ester and polymers that are modified to hydrophobic.